BioCentury
ARTICLE | Clinical News

IV TRC105: Phase II data

September 21, 2015 7:00 AM UTC

An open-label, U.S. Phase II compassionate use trial in a single patient with choriocarcinoma showed that once-weekly 10 mg/kg IV TRC105 plus 10 mg/kg IV Avastin bevacizumab every 2 weeks led to an o...